BOSTON--(EON: Enhanced Online News)--Joslin Diabetes Center announces a research and development alliance with Johnson & Johnson Innovation and its affiliate Janssen Research & Development, LLC, to identify and advance early-stage, novel therapeutic projects for potential for commercialization and product development. The first joint project selected in the alliance will focus on identifying exercise-related drug targets for developing new diabetes treatments.
“Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”
“Joslin is uniquely positioned to translate findings in the laboratory into new approaches for treatment of diabetes, and our alliance with Johnson & Johnson Innovation and Janssen Research & Development is an excellent example of how we can move our early discoveries to the clinic with our complementary capabilities,” said Dr. Nandan Padukone, Ph.D., MBA, VP of Commercialization and Ventures at Joslin. “We will continue to explore other technologies with Johnson & Johnson Innovation and mechanisms such as venture creation to advance them quickly towards drug development.”
The new alliance is based on pioneering studies by Joslin researchers showing that exercise can train multiple tissues in the body that in turn stimulate metabolic improvements in other tissues. “The concept of tissue-to-tissue communication has been around for a while, but more recently we have realized that ‘trained’ tissues may communicate to beneficially affect other tissues,” said Laurie Goodyear, Ph.D., Co-Head of the Integrative Physiology and Metabolism Section at Joslin and senior investigator on this research presented earlier this year at the American Diabetes Association’s 73rd annual Scientific Sessions. “Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”
Joslin’s Office of Commercialization and Ventures (OCV) was created in 2011 to work closely with industry partners and deliver new research and clinical solutions to the diabetes community. The OCV has worked with companies in the pharmaceutical, biotechnology device, and food industries to help conduct research, clinical trials and develop product-driven strategic alliances. The OCV also works with Jenesis Biosciences, a for-profit small business, to incubate and accelerate novel technology opportunities to a commercially ready stage for venture spin-outs and for partner investments.
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
The Office of Commercialization & Ventures (OCV) is a business center of Joslin Diabetes Center focused on creating strategic relationships that will expand the reach of Joslin's research and clinical expertise and promote new products and services in diabetes, its complications and obesity. For more information, visit www.joslin.org/ocv.